UK Markets closed

Deinove SA (DNVVF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.50000.0000 (0.00%)
At close: 10:18AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.5000
Open0.5000
BidN/A x N/A
AskN/A x N/A
Day's range0.5000 - 0.5000
52-week range0.4706 - 0.5800
Volume1,895
Avg. volume0
Market cap15.181M
Beta (5Y monthly)1.04
PE ratio (TTM)N/A
EPS (TTM)-0.2330
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Deinove Announces the Opening of Receivership Proceedings

    DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, following the Company's request (press release published on October 28, 2022), the Montpellier Commercial Court decided on November 7, 2022 to open receivership proceedings (“procédure de redressement judiciaire”) with an observation period (“période d'observation”) of 6 weeks from

  • Globe Newswire

    DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS

    DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces having filed today a declaration of cessation of payments ("déclaration de cessation des paiements") and a request for receivership proceedings (“procédure de redressement judiciaire”) of the Company with the Montpellier Commercial Court. The employee representative bodies were notified

  • Globe Newswire

    DEINOVE - Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on October 17, 2022

    DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, informs its shareholders that the Extraordinary General Meeting (AGE) held on October 17, 2022 has followed the recommendations of the Board of Directors, and adopted all the resolutions that the Board was favorable to, i.e. 10 out of the 11 resolutions. The shareholders taking part in the vote ow